Abstract
Since its discovery in 1984, the beta amyloid peptide has treaded the boards of neurosciences as the star molecule in Alzheimer’s disease pathogenesis. In the last decade, however, this vision has been challenged by evidence-based medicine showing the almost complete failure of clinical trials that experimented anti-amyloid therapies with great hopes. Moreover, data have accumulated which clearly indicate that this small peptide plays a key role in the physiological processes of memory formation. In the present review, we will discuss the different aspects of the amyloid cascade hypothesis, highlighting its pros and cons, and we will analyse the results of the therapeutic approaches attempted to date that should change the direction of Alzheimer’s disease research in the future.
Keywords: Alzheimer's disease, beta amyloid, clinical trials, LTP, memory, anti-amyloid therapy.
Graphical Abstract
Current Neuropharmacology
Title:The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind
Volume: 15 Issue: 6
Author(s): Roberta Ricciarelli*Ernesto Fedele*
Affiliation:
- Department of Experimental Medicine, Section of General Pathology, University of Genova, Genova,Italy
- Department of Pharmacy, Section of Pharmacology and Toxicology, University of Genova, Genova,Italy
Keywords: Alzheimer's disease, beta amyloid, clinical trials, LTP, memory, anti-amyloid therapy.
Abstract: Since its discovery in 1984, the beta amyloid peptide has treaded the boards of neurosciences as the star molecule in Alzheimer’s disease pathogenesis. In the last decade, however, this vision has been challenged by evidence-based medicine showing the almost complete failure of clinical trials that experimented anti-amyloid therapies with great hopes. Moreover, data have accumulated which clearly indicate that this small peptide plays a key role in the physiological processes of memory formation. In the present review, we will discuss the different aspects of the amyloid cascade hypothesis, highlighting its pros and cons, and we will analyse the results of the therapeutic approaches attempted to date that should change the direction of Alzheimer’s disease research in the future.
Export Options
About this article
Cite this article as:
Ricciarelli Roberta*, Fedele Ernesto*, The Amyloid Cascade Hypothesis in Alzheimer’s Disease: It’s Time to Change Our Mind, Current Neuropharmacology 2017; 15 (6) . https://dx.doi.org/10.2174/1570159X15666170116143743
DOI https://dx.doi.org/10.2174/1570159X15666170116143743 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Current Status Of Short Synthetic Peptides As Vaccines
Medicinal Chemistry Methamphetamine and HIV Infection, Role in Neurocognitive Dysfunction
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Systems Biology of Apoptosis and Survival: Implications for Drug Development
Current Pharmaceutical Design Listeria-Based Anti-Infective Vaccine Strategies
Recent Patents on Anti-Infective Drug Discovery Identification of Pyrazole Derivative as an Antiviral Agent Against Chikungunya Through HTVS
Letters in Drug Design & Discovery Neurocysticercosis: The Enigmatic Disease
Central Nervous System Agents in Medicinal Chemistry Pharmacokinetics, Pharmacodynamics and Clinical Use of Valganciclovir in Newborns with Symptomatic Congenital Cytomegalovirus Infection
Current Drug Metabolism Pathways by Which Aβ Facilitates Tau Pathology
Current Alzheimer Research The Multiple Layers of Signaling Selectivity at Protease-Activated Receptors
Current Pharmaceutical Design Inhibitor at the Gates, Inhibitor in the Chamber: Allosteric and Competitive Inhibitors of the Proteasome as Prospective Drugs
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Pentapeptides as Minimal Functional Units in Cell Biology and Immunology
Current Protein & Peptide Science Influence of Culture in Obsessive-compulsive Disorder and Its Treatment
Current Psychiatry Reviews Kynurenine System and Multiple Sclerosis, Pathomechanism and Drug Targets with An Emphasis on Laquinimod
Current Drug Targets Therapeutic Options in Prevention and Treatment of Aspartoacylase Gene Mutation Resulting Abnormalities in Canavan Disease
Current Pharmacogenomics Detection of the M. pneumonia in Synovial Fluid of Children with Negative Culture Arthritis: A Cross Sectional Study in Tehran, Iran
Infectious Disorders - Drug Targets Neurotransmitter Effects in Human Immunodeficiency Virus (HIV) and Simian Immuno-Deficiency Virus (SIV) Infection
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Mouse Models of Autoimmune Uveitis
Current Pharmaceutical Design Patent Selections
Recent Patents on Anti-Cancer Drug Discovery Heparan Sulphate Proteoglycans and Viral Vectors : Ally or Foe?
Current Gene Therapy Disease Modifying Therapeutic Strategies in Alzheimers Disease Targeting the Amyloid Cascade
Current Neuropharmacology